These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33919281)

  • 41. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer.
    Liu Y; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    BMC Cancer; 2015 Mar; 15():194. PubMed ID: 25884806
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.
    Broeks A; Urbanus JH; Floore AN; Dahler EC; Klijn JG; Rutgers EJ; Devilee P; Russell NS; van Leeuwen FE; van 't Veer LJ
    Am J Hum Genet; 2000 Feb; 66(2):494-500. PubMed ID: 10677309
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study.
    Einarsdóttir K; Rosenberg LU; Humphreys K; Bonnard C; Palmgren J; Li Y; Li Y; Chia KS; Liu ET; Hall P; Liu J; Wedrén S
    Breast Cancer Res; 2006; 8(6):R67. PubMed ID: 17132159
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations.
    Kaufman B; Laitman Y; Gronwald J; Winqvist R; Irmejs A; Lubinski J; Pylkäs K; Gardovskis J; Miklasevics E; Friedman E
    Fam Cancer; 2009; 8(4):473-8. PubMed ID: 19609724
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.
    Kilpivaara O; Bartkova J; Eerola H; Syrjäkoski K; Vahteristo P; Lukas J; Blomqvist C; Holli K; Heikkilä P; Sauter G; Kallioniemi OP; Bartek J; Nevanlinna H
    Int J Cancer; 2005 Feb; 113(4):575-80. PubMed ID: 15472904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report.
    Andrés R; Menao S; Arruebo M; Quílez E; Cardiel MJ
    Breast Cancer Res Treat; 2019 Oct; 177(3):767-770. PubMed ID: 31292799
    [TBL] [Abstract][Full Text] [Related]  

  • 48. "I wish that there was more info": characterizing the uncertainty experienced by carriers of pathogenic ATM and/or CHEK2 variants.
    Reyes KG; Clark C; Gerhart M; Newson AJ; Ormond KE
    Fam Cancer; 2022 Apr; 21(2):143-155. PubMed ID: 33855648
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population.
    Meiss AE; Thomas M; Modesitt SC; Ring KL; Atkins KA; Mills AM
    Hum Pathol; 2018 Dec; 82():20-31. PubMed ID: 29958926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes.
    Wei G; Teng M; Rosa M; Wang X
    Breast Cancer Res; 2022 Feb; 24(1):11. PubMed ID: 35135604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing.
    Slavin TP; Coffee B; Bernhisel R; Logan J; Cox HC; Marcucci G; Weitzel J; Neuhausen SL; Mancini-DiNardo D
    Cancer Genet; 2019 Jun; 235-236():31-38. PubMed ID: 31056428
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Histopathological features of breast cancer in carriers of ATM gene variants.
    Balleine RL; Murali R; Bilous AM; Farshid G; Waring P; Provan P; Byth K; Thorne H; ; Kirk JA
    Histopathology; 2006 Nov; 49(5):523-32. PubMed ID: 17064299
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Comparison between CHEK2*1100delC/I157T Mutation Carrier and Noncarrier Breast Cancer Patients: A Clinicopathological Analysis.
    Huszno J; Budryk M; Kołosza Z; Tęcza K; Pamuła Piłat J; Nowara E; Grzybowska E
    Oncology; 2016; 90(4):193-8. PubMed ID: 26991782
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protein-truncating variants in moderate-risk breast cancer susceptibility genes: a meta-analysis of high-risk case-control screening studies.
    Aloraifi F; McCartan D; McDevitt T; Green AJ; Bracken A; Geraghty J
    Cancer Genet; 2015 Sep; 208(9):455-63. PubMed ID: 26250988
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Stolarova L; Kleiblova P; Janatova M; Soukupova J; Zemankova P; Macurek L; Kleibl Z
    Cells; 2020 Dec; 9(12):. PubMed ID: 33322746
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Landscape of Somatic Genetic Alterations in Breast Cancers from
    Mandelker D; Kumar R; Pei X; Selenica P; Setton J; Arunachalam S; Ceyhan-Birsoy O; Brown DN; Norton L; Robson ME; Wen HY; Powell S; Riaz N; Weigelt B; Reis-Filho JS
    JNCI Cancer Spectr; 2019 Jun; 3(2):pkz027. PubMed ID: 31360903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.
    de Bock GH; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
    J Med Genet; 2004 Oct; 41(10):731-5. PubMed ID: 15466005
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Survival from breast cancer in patients with CHEK2 mutations.
    Huzarski T; Cybulski C; Wokolorczyk D; Jakubowska A; Byrski T; Gronwald J; Domagała P; Szwiec M; Godlewski D; Kilar E; Marczyk E; Siołek M; Wiśniowski R; Janiszewska H; Surdyka D; Sibilski R; Sun P; Lubiński J; Narod SA
    Breast Cancer Res Treat; 2014 Apr; 144(2):397-403. PubMed ID: 24557336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.